Spanish study links RSV antibody to 86% drop in infant hospitalizations
Nirsevimab, a long-acting antibody given to every infant in one Spanish region, cut RSV hospitalizations by 86% compared to previous seasons, according to a new study out of Valladolid University. Babies under six months — the group hit hardest by RSV every winter — saw the biggest drop, with pediatric intensive care admissions falling sharply too. Unlike a traditional vaccine, the shot delivers ready-made antibodies directly, which matters for newborns whose immune systems are still developing. Several European countries and the U.S. have already added it to routine infant care, and early data abroad echo the Spanish results. The remaining challenge is making sure families in lower-income countries, where RSV hits hardest, aren’t left waiting.









